Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Recruiting

Phase 1

Phase 2

Bevacizumab & MicrobubbleSafety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)

Sponsor:

NaviFUS Corporation

Code:

NCT06329570

Conditions

Glioblastoma Multiforme

Glioblastoma

Glioma

Brain Tumor

Neoplasms

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

NaviFUS System

Lumason

Bevacizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-07. This information was provided to ClinicalTrials.gov by NaviFUS Corporation on 2026-04-09.